One- and Two-Year Outcomes of Switching to a Dolutegravir-Based ART Regimen: An Observational Emulation of Sequential Target Trials

Amy Zheng, Eleanor J Murray, Alana T Brennan, Ross Greener, Emma M Kileel, Jacob Bor, Willem D F Venter, Pedro T Pisa, Matthew P Fox, Mhairi Maskew · 2026

Read One- and Two-Year Outcomes of Switching to a Dolutegravir-Based ART Regimen: An Observational Emulation of Sequential Target Trials by Amy Zheng, Eleanor J Murray, Alana T Brennan, Ross Greener, Emma M Kileel, Jacob Bor, Willem D F Venter, Pedro T Pisa, Matthew P Fox, Mhairi Maskew (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13132165.txt.

Description

Zheng and coauthors weigh gains from a switch to a newer HIV drug. Trials of the switch left out patients with poor virus control. In real clinics, doctors switch such patients all the same. The team mimicked a trial with real clinic records.

Records came from a large HIV clinic in Johannesburg, South Africa. Patients were on the older drug at each trial start. All were aged 16 or more and not pregnant. The team tracked stay in care and virus control at one and two years. Their method aims to give fair, trial-like answers from real data.

Catalog record

CREATORAmy Zheng, Eleanor J Murray, Alana T Brennan, Ross Greener, Emma M Kileel, Jacob Bor, Willem D F Venter, Pedro T Pisa, Matthew P Fox, Mhairi Maskew
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE34 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13132165

Browse the full library · About the Tower of Babel